LEO Pharma launches Enstilar in UK for plaque psoriasis

Danish privately-held LEO Pharma has launched its psoriasis treatment Enstilar (calcipotriene/betamethasone dipropionate) in the UK.

Enstilar is the first fixed-combination foam spray for the treatment of plaque psoriasis in the UK and comes with the support of strong Phase II and Phase III data, the company noted.

These data show that Enstilar is a more effective topical combination treatment than those currently available and is generally well-tolerated, with more than half of patients in clinical trials experiencing significant visible signs of improvement within four weeks and some patients seeing improvements at one week.